Abstract

Despite successful therapeutic options for estrogen receptor-α (ERα)+ breast cancer, resistance to endocrine therapy frequently occurs leading to tumor recurrence. In addition to intrinsic changes in the cancer cells, herein we demonstrate that tumor cell-microenvironment interactions can drive recurrence at specific sites. By using two ERα+ cell lines derived from spontaneous mammary carcinomas in STAT1−/− mice (SSM2, SSM3), we establish that the bone microenvironment offers growth advantage over primary site or lung in the absence of ovarian hormones. While SSM3 did not engraft at primary and skeletal locations in the absence of estrogen, SSM2 selectively grew in bone of ovariectomized mice and following administration of aromatase inhibitors. However, SSM2 growth remained hormone-dependent at extraskeletal sites. Unexpectedly, bone-residing SSM2 cells retained ERα expression and JAK2/STAT3 activation regardless of the hormonal status. These data position the bone microenvironment as a unique site for acquisition of tumor/estrogen independency and identify the first ERα+ hormone-independent tumor model in immunocompetent mice.

Highlights

  • The skeleton is the most common site of breast cancer metastasis [1]

  • SSM2 and SSM3 breast cancer cell lines have been derived from primary tumors in STAT1−/− mice and express estrogen receptor-α (ERα) and PR [14]

  • In this study we have used SSM2 and SSM3 ERα+/PR+ murine cell lines derived from spontaneous breast carcinomas in mice lacking STAT1, a transcription factor associated with tumor progression in ERα+ breast cancer patients [14]

Read more

Summary

Introduction

The skeleton is the most common site of breast cancer metastasis [1]. Breast cancer is the most common malignancy and the leading cause of cancer death among women worldwide [2]. Several human ER+ breast cancer cell lines, such as MCF7, T47D and ZR75 cells, can develop estrogen-independent growth after long-term drug exposure in vitro and be used as breast cancer estrogen-independent tumor models in vivo [11, 12]. These cell lines are poorly invasive and rarely metastasize. We find that while SSM3 cells do not grow in bone of OVX animals, SSM2 cells become resistant to hormone-deprivation in the bone microenvironment To our knowledge, this is the first preclinical model describing hormone-independent growth of ERα+/PR+ breast tumor cells in the context of bone metastasis in immunocompetent animals

Results
Discussion
Conflicts of Interest
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call